-
Biocon Biologics biosimilars for osteoporosis, cancer-related bone disease gets FDA nod
21 Sep 2025 15:25 GMT
… Bengaluru-based Biocon fully integrated subsidiary Biocon Biologics announced that … ,000 crore).
Alongside Biocon, Denosumab biosimilars is also … Tambe, CEO and MD, Biocon Biologics, said, “With … are further expanding our oncology care portfolio.”
Published On …
-
Growth Factors Market to Reach $4.07 Billion by 2033 | Driven by Regenerative Medicine & Oncology | DataM Intelligence
19 Sep 2025 13:00 GMT
… biotechnology, regenerative medicine, and oncology research. Growth factors are naturally … according to DataM Intelligence.
➤ Oncology remains the leading application segment … Roche Ltd.
• Amgen Inc.
• Biocon Limited
• Novartis AG
• GenScript Biotech …
-
FDA Approves Biocon Biologics' Denosumab Biosimilars: Bosaya and Aukelso
19 Sep 2025 01:28 GMT
… The approvals, granted to Biocon Biologics, will provide more … and managing director of Biocon Biologics, stated that the … are further expanding our oncology care portfolio," he … denosumab biosimilars. News release. Biocon Biologics. September 17, 2025. …
-
Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
18 Sep 2025 05:23 GMT
… Thursday after its subsidiary, Biocon Biologics, received U.S. … market adoption.
On Wednesday, Biocon Biologics said the FDA … from selling the metabolic, oncology, and critical care portfolio … Eris Lifesciences.
On Wednesday, Biocon shares closed 1.6% …
-
Biocon Biologics gets US FDA nod for two drugs to treat osteoporosis, bone loss
18 Sep 2025 00:43 GMT
… , a subsidiary of Biocon Ltd, on Wednesday said it … and Xgeva $1.6 billion.
Biocon Biologics CEO & MD Shreehas … approvals expand the company’s oncology and bone health portfolio and …
-
Biocon Biologics wins USFDA nod for Bosaya and Aukelso, Denosumab Biosimilars
17 Sep 2025 20:02 GMT
Bengaluru: Biocon Biologics Ltd., a fully … biosimilars company and subsidiary of Biocon Ltd., has announced that … CEO & Managing Director, Biocon Biologics, said, “The FDA’s … we are further expanding our oncology care portfolio. This achievement underscores …
-
Oncology Biosimilars Market to Hit USD 24 Billion by 2035 | Sandoz, Pfizer, Celltrion Lead – Fact.MR
20 Aug 2025 11:30 GMT
… :
Technological advancements are transforming the oncology biosimilars landscape, emphasizing scalability, safety … Laboratories Ltd. (10-13%), and Biocon (9-12%), collectively holding over … Europe. Dr. Reddy’s and Biocon focus on emerging markets, offering …
-
Biocon Biologics posts strong Q1 growth as North America, Europe deliver
09 Aug 2025 01:07 GMT
… And primarily on our oncology franchise," chief executive … accelerate towards growth.
Biocon Biologics acquired the global … biopharmaceutical company," Biocon’s executive chairperson Kiran … its stake in Biocon Biologics, Biocon concluded its first …
-
Biocon reports 95% YoY decline in net profit, operating revenue up 15%
07 Aug 2025 18:16 GMT
… the sale of metabolic, oncology and critical care portfolio … Kiran Mazumdar-Shaw, Chairperson, Biocon Group.
“With execution momentum … beyond,” said Shaw.
Biocon concluded its first equity … CEO & Managing Director, Biocon.
“We remain focused on …
-
Biocon Foundation and IISc on World Head & Neck Cancer Day called for oral cancer elimination
29 Jul 2025 12:09 GMT
… CSR) arm of the Biocon Group, in association with … Dr Kiran Mazumdar-Shaw, chairperson, Biocon Group said, “ With IISc … Dr Anupama Shetty, mission director, Biocon Foundation, said, “We have … Dr Kumar Prabhash, Medical Oncologist, Tata Memorial Hospital. These …
About
© 1995-2025